Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 13/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.33 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.33 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.33 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.33 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.33 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.33 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.33 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.33 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718662 | 0.86 | HTR2C (0.47) | HTR2AHTR2CHTR2BDRD2ADCY6 | |
| Trifluoroacetic Acid SCHEMBL719124 | 0.84 | PTPN1 (0.40) | KDM1ADRD2 | |
| Trifluoroacetic Acid SCHEMBL722173 | 0.82 | ALDH1A1 (0.40) | KDM1AHTR2AHTR2CHTR2BDRD2 | |
| Trifluoroacetic Acid SCHEMBL720167 | 0.81 | KDM1A (0.39) | KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL722817 | 0.76 | ESR1 (0.51) | DRD2 | |
| Trifluoroacetic Acid SCHEMBL4915477 | 0.73 | DRD2 (0.59) | KDM1AHTR2AHTR2CHTR2BDRD2 | |
| Trifluoroacetic Acid SCHEMBL722169 | 0.72 | AR (0.38) | KDM1AADCY6ADCY3ADCY9ADCY5 | |
| Trifluoroacetic Acid SCHEMBL15282793 | 0.71 | HTR2C (0.44) | KDM1AHTR2CHTR2B | |
| Trifluoroacetic Acid SCHEMBL5451230 | 0.70 | HTR2C (0.61) | KDM1AHTR2AHTR2CHTR2BDRD2 | |
| Trifluoroacetic Acid SCHEMBL718879 | 0.69 | PDGFRB (0.36) | KDM1AHTR2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010096384-A2 | FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA2, CHRNA5, CHRNA10 | KDM1A 2596/4885HTR2A 311/4885HTR2C 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.